BeOne Medicines Says FDA Grants Priority Review to Brukinsa Combination
BeOne Medicines said the FDA granted priority review to a Brukinsa combination for mantle cell lymphoma.
Related stories
UK CMA Opens Phase 1 Merger Probe Into Fleet Services Deal
The UK Competition and Markets Authority has launched a Phase 1 merger probe into NRG Fleet Services-Specialist Fleet Services.
M impact | REGULATION | Nov 04, 2026, 03:36 PM UTC
Colombia's JEP Charges Rodrigo Londoño and Former FARC Commanders
Colombia's Special Jurisdiction for Peace has charged Rodrigo Londoño and other former FARC commanders with crimes against humanity.
L impact | REGULATION | Nov 04, 2026, 03:35 PM UTC
Xavier Becerra Wins California Governor's Race
Becerra will be the first Latino elected governor of California in more than 150 years.
M impact | REGULATION | Nov 04, 2026, 03:31 PM UTC
Class Action Filed Against Webull Corporation Over Alleged Securities Violations
A class action has been filed against Webull Corporation. The supplied report does not specify further details.
M impact | REGULATION | Nov 04, 2026, 03:15 PM UTC
UK Supreme Court Hears Challenge to Palestine Action Ban
A challenge to the UK ban on Palestine Action is before the Supreme Court.
L impact | REGULATION | Nov 04, 2026, 03:11 PM UTC
UK Opens Public-Interest Investigation Into Sky-ITV Media Deal
The U.K. government announced a public-interest investigation into Sky’s planned takeover of ITV’s media arm. The available report says Culture Secretary Lisa Nandy will intervene;
L impact | REGULATION | Nov 04, 2026, 02:54 PM UTC